Beta Bionics (NASDAQ:BBNX) Now Covered by Stifel Nicolaus

Stifel Nicolaus began coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research note published on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $25.00 target price on the stock.

A number of other research analysts also recently commented on the company. Robert W. Baird initiated coverage on Beta Bionics in a research report on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price for the company. Piper Sandler started coverage on shares of Beta Bionics in a research note on Monday. They issued an “overweight” rating and a $26.00 price objective for the company. Baird R W upgraded shares of Beta Bionics to a “hold” rating in a research report on Thursday, February 20th. Leerink Partners assumed coverage on shares of Beta Bionics in a report on Monday. They issued an “outperform” rating and a $28.00 price target for the company. Finally, LADENBURG THALM/SH SH started coverage on Beta Bionics in a research note on Thursday, February 20th. They set a “neutral” rating and a $20.00 price objective on the stock. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Beta Bionics has an average rating of “Moderate Buy” and an average price target of $24.83.

Beta Bionics Price Performance

Shares of Beta Bionics stock opened at $19.99 on Monday. Beta Bionics has a 12 month low of $18.67 and a 12 month high of $24.50.

Insider Activity at Beta Bionics

In related news, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the purchase, the insider now owns 3,901,599 shares of the company’s stock, valued at $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mike Mensinger purchased 33,350 shares of Beta Bionics stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the purchase, the insider now directly owns 59,019 shares in the company, valued at $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.